Last A$0.57 AUD
Change Today 0.00 / 0.00%
Volume 16.0K
As of 9:31 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

bionomics ltd (BNO) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/2/13 - A$0.89
52 Week Low
06/4/14 - A$0.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIONOMICS LTD (BNO)

Related News

No related news articles were found.

bionomics ltd (BNO) Related Businessweek News

No Related Businessweek News Found

bionomics ltd (BNO) Details

Bionomics Limited discovers and develops biopharmaceuticals for the treatment of cancer and disorders of the central nervous system in Australia, France, and the United States. The company develops small molecule and antibody therapeutics in the areas of cancer, anxiety, depression, and Alzheimer's disease. Its oncology approach includes cancer stem cell therapeutics, as well as vascular disruption in solid tumors. The company’s product pipeline includes BNC105, a novel compound in Phase II clinical trials to disrupt the blood vessels that nourish tumours in cancer treatment; and BNC101, a monoclonal antibody that targets cancer stem cells. It is also developing BNC210/IW-2143 for the treatment of anxiety disorders; BNC375, a small molecule therapeutic for the treatment of cognitive impairment in Alzheimers's disease; and Kv1.3 inhibitors for the treatment of inflammatory disorders. In addition, the company, through its subsidiary, Neurofit SAS, offers contract research services. It has collaboration, research, and licensing agreements with Ironwood Pharmaceuticals, Inc.; Merck & Co.; Cancer Therapeutics Cooperative Research Center; Genmab A/S; Laboratory Corporation of America; Athena Diagnostics, Inc.; and Genetic Technologies Limited. The company was founded in 1998 and is based in Thebarton, Australia.

Founded in 1998

bionomics ltd (BNO) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$407.6K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$160.8K
Chief Medical Officer
Total Annual Compensation: A$378.9K
Head of Neurofit Research
Total Annual Compensation: A$188.7K
Vice President of Research & Development
Total Annual Compensation: A$208.3K
Compensation as of Fiscal Year 2014.

bionomics ltd (BNO) Key Developments

Bionomics Presents BNC105 Phase II Renal Cancer Trial Biomarker Data

Bionomics Limited presented new important data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the European Society for Medical Oncology congress in Madrid, Spain. The data emphasizes the plasma biomarker profile associated with favourable outcomes for patients treated with BNC105. Throughout the clinical trials of BNC105 Bionomics has analyzed a panel of blood biomarkers. This was done to detect changes resulting from the administration of BNC105 and to determine whether such changes can indicate BNC105 clinical benefit. A most exciting aspect of this biomarker analysis has emerged from the randomised Phase II DisrupTOR-1 trial. As reported in March, 136 patients were enrolled and segregated in two treatment arms (69 in the BNC105 + Afinitor arm and 67 in the Afinitor-only arm). The primary endpoint of the study was to improve Progression Free Survival (PFS) from 36% at six months in the Afinitor-only arm to 60% PFS in the BNC105 + Afinitor arm. The initial data indicated that, in an unselected population, the proportion of PFS patients were similar between the two arms. However, blood samples were obtained from 44 patients before and after treatment with BNC105 in the BNC105 + Afinitor arm. This large sample size enabled statistical correlation of blood biomarker changes with disease status at six months of treatment. This correlation analysis revealed four biomarkers can be used to significantly enrich treatment success for this patient group treated with BNC105 plus Afinitor. 57% of patients were positive for the 4 biomarker signature, with 60% of these being disease free at six months. In contrast, only 5% of the patients that were negative for the 4 biomarker signature were disease free at six months. It is noteworthy that for this sizeable patient group the 60% six month PFS primary endpoint target was achieved.

Bionomics Ltd. Announces Audited Group Earnings Results for the Full Year Ended June 30, 2014

Bionomics Ltd. announced audited group earnings results for the full year ended June 30, 2014. For the year, the company reported revenue of $27,545,996, compared with $11,825,956 for the period to June 30, 2013. The operating profit after tax of the group for the period was $3,206,616 which was a result of the licensing of the BNC375 program to Merck & Co announced on June 24, 2014 and reflects the company's continued execution of its business plan.

Bionomics Ltd. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:30 PM

Bionomics Ltd. Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 02:30 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNO:AU A$0.57 AUD 0.00

BNO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNO.
View Industry Companies

Industry Analysis


Industry Average

Valuation BNO Industry Range
Price/Earnings 69.3x
Price/Sales 8.8x
Price/Book 4.9x
Price/Cash Flow 68.8x
TEV/Sales 7.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIONOMICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at